These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21036758)

  • 41. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
    Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
    Ansari J; Hussain SA; Zarkar A; Tanguay JS; Bliss J; Glaholm J
    Oncol Rep; 2008 Oct; 20(4):891-6. PubMed ID: 18813832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L
    Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
    Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.
    Dabkara D; Ganguly S; Biswas B; Ghosh J
    Indian J Cancer; 2018; 55(1):94-97. PubMed ID: 30147102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
    Rezvani H; Haghighi S; Ghadyani M; Attarian H
    Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients.
    Takenaka A; Yamada Y; Kurahashi T; Soga H; Miyake H; Fujisawa M
    Int J Urol; 2008 Jan; 15(1):106-9. PubMed ID: 18184188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.
    Nelius T; Rinard K; Filleur S
    Cancer Treat Rev; 2011 Oct; 37(6):444-55. PubMed ID: 21277093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
    Helley D; Banu E; Bouziane A; Banu A; Scotte F; Fischer AM; Oudard S
    Eur Urol; 2009 Sep; 56(3):479-84. PubMed ID: 18585841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
    Görn M; Habermann CR; Anige M; Thöm I; Schuch G; Andritzky B; Brandl S; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C; Laack E
    Onkologie; 2008 Apr; 31(4):185-9. PubMed ID: 18418020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
    Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
    Cicero G; De Luca R
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):325-31. PubMed ID: 21528780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
    BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.